Antibody for detecting epithelial ovarian cancer marker and method for diagnosing epithelial ovarian cancer
It is intended to find a highly specific epithelial ovarian cancer marker and to provide an antibody capable of specifically recognizing and detecting the marker or a fragment of the antibody. The present invention provides an anti-β1,6-N-acetylglucosaminyltransferase 5B antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase β1,6-N-acetylglucosaminyltransferase 5B as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.
1. A method for diagnosis of epithelial ovarian cancer, comprising:
(a) quantitatively detecting a β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment present in a sample derived from a test subject using at least one anti-β-1,6-N-acetylglucosaminyltransferase 5B monoclonal antibody, or antibody fragment thereof, and
(b) determining that the test subject is diagnosed to be likely to have epithelial ovarian cancer when the results of quantitatively detecting the β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment are greater than a predetermined cut-off value,
wherein the predetermined cut-off value is the 95th percentile of the quantitative detection results of the β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment in the sample derived from normal individuals or patients other than epithelial ovarian cancer patients,
wherein the anti-β-1,6-N-acetylglucosaminyltransferase 5B monoclonal antibody is produced by a hybridoma identified by International Accession No. FERM BP-11496, FERM BP-11497, FERM BP-11498, or FERM BP-11499.
2. The method for diagnosis of epithelial ovarian cancer of claim 1 , wherein the β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment comprising an epitope recognized by the anti-β-1,6-N-acetylglucosaminyltransferase 5B monoclonal antibody, or the antibody fragment thereof is the whole or a part of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.
3. The method for diagnosis of epithelial ovarian cancer of claim 1 , wherein two anti-β-1,6-N-acetylglucosaminyltransferase 5B monoclonal antibodies are used to detect the β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment.
4. A method for diagnosis of epithelial ovarian cancer, comprising:
(a) quantitatively detecting a β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment present in a sample derived from a test subject using at least one monoclonal antibody or antibody fragment thereof, and
(b) determining that the test subject is diagnosed to be likely to have epithelial ovarian cancer when the results of quantitatively detecting the β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment are greater than a predetermined cut-off value of 4.0 ng/mL,
wherein the monoclonal antibody is produced by a hybridoma identified by International Accession No. FERM BP-11496, FERM BP-11497, FERM BP-11498, or FERM BP-11499.
5. The method for diagnosis of epithelial ovarian cancer of claim 1 , wherein the sample is a body fluid, a peritoneal lavage fluid, or a tissue.
6. The method for diagnosis of epithelial ovarian cancer of claim 4 , wherein two anti-β-1,6-N-acetylglucosaminyltransferase 5B monoclonal antibodies are used to detect the β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment.